Drug Discovery · Antwerp, Belgium · Founded 2017 · Privately Held (backing)
Developer of fibrotic disease treatments intended to preserve and restore organ function in fibrotic. AgomAb is based in Antwerp, Belgium and was founded in 2017. Its last known valuation is $416 million. It has raised $334 million across 1 recorded round; the latest was a $101 million Series C in Oct 2023.
Last price · $/share
—
Implied valuation
$415.6M
Total raised
$334.0M
Last round
Later Stage VC (Series C)
Oct 2023
Team — not yet on record
No current team members for AgomAb are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of AgomAb with a free account
·The complete investor list: 17 names
·Watch AgomAb: the Monday email on marks, rounds and moves
